REFERENCES
1. Dedov I.I., Mel’nichenko G.A., Fadeev V.V. Endocrinology: textbook. 3rd ed., revised and supplemented. Moscow, 2015: 416 p. (in Russian)
2. Alzahrani T., Nguyen T., et al. Cardiovascular disease risk factors and myocardial infarction in the transgender population. Circ Cardiovasc Qual Outcomes. 2019; 12 (4): e005597.
3. Jian-Di L., Yan-Qing Wu. Anabolic-androgenic steroids and cardiovascular risk. Chin Med J (Engl). 2019; 132 (18): 2229–36.
4. Williams Br., Mancia G., et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018; 39 (33): 3021–104.
5. Vermeulen A., Verdonck L., Kaufman J.M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999; 84 (10): 3666–72. DOI: https://doi.org/10.1210/jcem.84.10.6079
6. STATISTICA help [Internet], 2019. STATISTICA automated neuronal networks overviews – network types. The multilayer perceptron neural networks. URL: http://documentation.statsoft.com/STATISTICAHelp.aspx?path=SANN/Overview/SANNNeuralNetworksAnOverview (date of access April 11, 2019)
7. Zhu J., Wittemans L.B.L., Lindgren C., Hirschhorn J.N., et al. A genetically defined male counterpart of polycystic ovary syndrome: evidence for ovarian-independent pathogenesis. J Endocr Soc, 2021; 5 (Suppl 1, April-May): A773–4.
8. Gillis E., Sullivan J. Sex differences in hypertension: recent advances. Hypertension. 2016; 68 (6): 1322–7.
9. Chasland L., Green D., et al. Effects of testosterone treatment, with and without exercise training, on ambulatory blood pressure in middle-aged and older men. Clin Endocrinol (Oxf). 2021; 95 (1): 176–86.
10.Isidoro L., Ferrer M., et al. Vasoactive androgens: vasorelaxing effects and their potential regulation of blood pressure. Endocr Res. 2018; 43 (3): 166–75.
11.Swerdloff R., Dudley R., et al. Dihydrotestosterone: biochemistry, physiology, and clinical implications of elevated blood levels. Endocr Rev. 2017; 38 (3): 220–54.
12.Iorga A., Cunningham C., Moazeni S., et al. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biol Sex Differ. 2017; 8 (1): 33.
13.Teoh H., Quan A., Leung S.W., et al. Differential effects of 17beta-estradiol and testosterone on the contractile responses of porcine coronary arteries. Br J Pharmacol. 2000; 129 (7): 1301–8.
14.Caceres B.A., Carl G.Jr. Cardiovascular health concerns in sexual and gender minority populations. Nat Rev Cardiol. 2021; 18 (4): 227–8.
15.Streed C.G.Jr., Harfouch O., Marvel F., et al. Cardiovascular disease among transgender adults receiving hormone therapy: a narrative review. Ann Intern Med. 2017; 167 (4): 256–67.
16.Reckelhoff J.F., Zhang H., Granger J.P. Testosterone exacerbates hypertension and reduces pressure-natriuresis in male spontaneously hypertensive rats. Hypertension. 1998; 31 (1 pt 2): 435–9.
17.Kario K., Saito I., Kushiro T., Teramukai S., et al. Home blood pressure and cardiovascular outcomes in patients during antihypertensive therapy: primary results of HONEST, a large-scale prospective, real-world observational study. Hypertension. 2014; 64: 989–96.
18.Kario K., Saito I., Kushiro T., Teramukai S., et al. Morning home blood pressure is a strong predictor of coronary artery disease: the HONEST study. J Am Coll Cardiol. 2016; 67: 1519–27.